博雅品牌怎么样 申请店铺

外推网助力博雅品牌出海！将品牌入驻外推网，定制博雅品牌推广信息，可以显著提高博雅产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

博雅控股集团是一家在生命健康领域具有广泛影响力的产业集团，业务范围涉及干细胞存储与临床应用，肿瘤免疫技术，动物种业技术的研发与产业化应用，动物商业克隆，美容美体与抗衰老，基因检测与精准医疗，药物研发和疾病模式等。

在干细胞技术及应用领域，博雅已经形成完整的产业链。在产业链上游，博雅通过收购赛斯卡医疗（Cesca Therapeutics(Nasdaq:KOOL)），成为干细胞自动化设备供应商，在产业链中游，博雅拥有国际标准的临床级干细胞库，是行业领先的干细胞整体解决方案供应商。在产业链下游，博雅是拥有美国FDA三期临床准入的干细胞企业，利用自体干细胞技术治疗严重肢体缺血症（CLI）的三期临床实验正在开展中。博雅拥有FDA批准上市的自体细胞治疗难愈性伤口技术。2017年7月，博雅控股集团通过赛斯卡医疗收购了CAR-T细胞制备自动化技术开发机构SynGen，进入肿瘤免疫疗法（CAR-T）领域。

在基因与克隆技术方面，博雅控股集团旗下的博雅基因主要专注于动物种业技术的研发与产业化应用的企业，拥有引领行业标准的物种资源自动化储存技术、前沿的动物克隆技术，业务板块包括畜牧良种繁育、遗传资源保存、犬类克隆、疾病模式动物研究。博雅基因将以生物技术、国际化的运营团队，致力于现代畜牧种业的改善。

自成立以来，博雅控股集团凭借强大的研发实力和行业影响力，获得了大量的社会荣誉。集团下属企业先后被中国贸促会评为“100家最有投资价值的品牌企业”,被央视评为“2012CCTV中国年度品牌”等行业殊荣。集团及合作的科学家团队分别于2012、2014年先后二次获得中国“国家创新团队”（每年全国仅四支）。2015年，集团荣获“中国科技创新行业领军品牌”。2016年，博雅与《科学》杂志共同设立“博雅·科学干细胞与再生医学杰出贡献奖”

经过10年发展，博雅控股集团已初步形成基于生命（人类、动物）健康的全产业链布局。博雅控股集团的长期愿景是打造一家具有竞争力的生命健康企业。

Boya holding group is an industry group with extensive influence in the field of life and health. Its business scope covers stem cell storage and clinical application, tumor immune technology, research and development and industrial application of animal seed industry technology, animal commercial cloning, beauty and anti-aging, gene detection and precision medicine, drug research and development and disease mode, etc. In the field of stem cell technology and application, Boya has formed a complete industrial chain. In the upstream of the industrial chain, through the acquisition of cesca therapeutics (NASDAQ: Kool), Boya has become a supplier of stem cell automation equipment. In the middle of the industrial chain, Boya has an international standard clinical stem cell bank, and is the leading supplier of stem cell overall solution. In the downstream of the industry chain, Boya is a stem cell enterprise with three-stage clinical access of FDA of the United States. The three-stage clinical experiment of treating severe limb ischemia (CLI) by using the technology of autologous stem cells is in progress. Boya has FDA approved self cell therapy for refractory wounds. In July 2017, Boya Holding Group acquired syngen, a car-t cell preparation automation technology development institution, through saiska medical, and entered the field of cancer immunotherapy (car-t). In terms of gene and cloning technology, Boya gene under Boya holding group mainly focuses on the R & D and industrial application of animal breeding technology, with leading industry standard automatic storage technology of species resources and cutting-edge animal cloning technology. Its business segments include animal breeding, genetic resource preservation, dog cloning and disease model animal research. With biotechnology and international operation team, Boya gene is committed to the improvement of modern animal husbandry and seed industry. Since its establishment, Boya holding group has won a lot of social honors with its strong R & D strength and industry influence. The group's subordinate enterprises have been rated as "100 most valuable brand enterprises" by China Council for the promotion of international trade and "2012cctv China brand of the year" by CCTV. In 2012 and 2014, the group and its team of scientists won the second "national innovation team" in China (only four in China each year). In 2015, the group won the title of "China's leading brand in science and technology innovation industry". In 2016, Boya and science jointly set up "Boya science stem cell and regenerative medicine outstanding contribution award". After 10 years of development, Boya holding group has initially formed the whole industrial chain layout based on life (human, animal) health. Boya holding group's long-term vision is to build a competitive life and health enterprise.

本文链接： https://brand.waitui.com/d78fd6b0d.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加